摘要
目的探讨微小RNA-122(miR-122)在糖尿病(DM)合并慢性乙型肝炎患者中的表达水平及临床意义。方法选取于合肥医科大学附属医院就诊的125例患者为研究对象,其中DM患者(DM组)50例,慢性乙型肝炎患者(HBV组)50例,DM合并慢性乙型肝炎患者(DM合并HBV组)25例,同时选取健康体检者20例为对照组。提取所有受试者的单个核细胞总RNA,采用实时荧光定量PCR检测各组miR-122水平,研究miR-122与各生化指标的相关性。结果DM合并HBV组miR-122水平高于HBV组、DM组和对照组(P<0.05)。HBV组乙型肝炎病毒DNA定量(HBV-DNA)水平高于DM合并HBV组(P<0.05);HBV组丙氨酸氨基转移酶、天门冬氨酸氨基转移酶水平高于对照组、DM组和DM合并HBV组(P<0.05)。DM合并HBV组miR-122水平与HBV-DNA、血糖(GLU)水平均呈正相关(r=0.238、0.231,P<0.05)。结论miR-122水平在DM合并慢性乙型肝炎患者中明显升高,并与HBV-DNA、GLU水平存在相关性,考虑其可能参与了疾病的发生、发展过程。
Objective To investigate the expression level and clinical significance of microRNA-122(miR-122)in patients with diabetes mellitus(DM)and chronic hepatitis B.Methods A total of 125 patients in the Affiliated Hospital of Zunyi Medical University were selected as the research objects,including 50 DM patients(DM group),50 chronic hepatitis B patients(HBV group),25 DM combined with chronic hepatitis B patients(DM combined with HBV group),and 20 healthy people were selected as the control group.The total RNA of mononuclear cells was extracted from all subjects,and the level of miR-122 in each group was detected by PCR.The correlation between miR-122 and biochemical indexes was studied.Results The level of miR-122 in DM combined with HBV group was higher than that in HBV group,DM group and control group(P<0.05).The level of HBV-DNA in HBV group was higher than that in DM combined with HBV group(P<0.05);the level of ALT and AST in HBV group was higher than that in control group,DM group and DM combined with HBV group(P<0.05).The level of miR-122 was positively correlated with the level of HBV-DNA and serum glucose(GLU)(r=0.238,0.231,P<0.05).Conclusion The level of miR-122 is significantly increased in patients with DM and chronic hepatitis B,and it is correlated with the levels of HBV-DNA and GLU.MiR-122 may be considered participating in the development of the disease.
作者
朱杰华
王江林
丰智雪
陈安林
黄健
杜文胜
ZHU Jiehua;WANG Jianglin;FENG Zhixue;CHEN Anlin;HUANG Jian;DU Wensheng(Department of Medical Laboratory,Affiliated Hospital of Zunyi Medical University,Zunyi,Guizhou 563000,China;Department of Clinical Laboratory,Renhuai Hospital of Traditional Chinese Medicine,Renhuai,Guizhou 564500,China;College of Medicine and Technology,Zunyi Medical University,Zunyi,Guizhou 563099,China)
出处
《检验医学与临床》
CAS
2020年第5期582-585,共4页
Laboratory Medicine and Clinic
基金
贵州省科技合作计划（黔科合LH字[2015]7478号）
合肥医学院附属医院基金项目（院字[2014]47号）
